162 related articles for article (PubMed ID: 35426370)
1. Tumor Treating Fields: killing two birds with one stone.
Lee J; Grabowski MM; Lathia JD
J Clin Invest; 2022 Apr; 132(8):. PubMed ID: 35426370
[TBL] [Abstract][Full Text] [Related]
2. Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma.
Chen D; Le SB; Hutchinson TE; Calinescu AA; Sebastian M; Jin D; Liu T; Ghiaseddin A; Rahman M; Tran DD
J Clin Invest; 2022 Apr; 132(8):. PubMed ID: 35199647
[TBL] [Abstract][Full Text] [Related]
3. Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma.
Xu S; Luo C; Chen D; Tang L; Chen L; Liu Z
Cell Death Dis; 2022 Aug; 13(8):721. PubMed ID: 35982032
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment.
Lee YJ; Seo HW; Baek JH; Lim SH; Hwang SG; Kim EH
Sci Rep; 2020 Jul; 10(1):12272. PubMed ID: 32704022
[TBL] [Abstract][Full Text] [Related]
5. A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights.
Li X; Liu K; Xing L; Rubinsky B
Radiol Oncol; 2023 Sep; 57(3):279-291. PubMed ID: 37665740
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Compatibility of Electric Tumor Treating Fields with Key Anti-tumoral T-Cell Functions.
Simchony H; Diamant D; Ram Z; Volovitz I
Isr Med Assoc J; 2019 Jul; 21(7):503. PubMed ID: 31507132
[TBL] [Abstract][Full Text] [Related]
7. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism.
Hong P; Kudulaiti N; Wu S; Nie J; Zhuang D
Expert Rev Mol Diagn; 2022 Jan; 22(1):19-28. PubMed ID: 34883030
[TBL] [Abstract][Full Text] [Related]
8. Tumor treating fields: a new standard treatment for glioblastoma?
Taillibert S; Le Rhun E; Chamberlain MC
Curr Opin Neurol; 2015 Dec; 28(6):659-64. PubMed ID: 26551239
[TBL] [Abstract][Full Text] [Related]
9. Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields.
Lan Y; Zhang S; Pan Y; Wang M; Chen G
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067345
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy.
Saria MG; Kesari S
Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S9-S13. PubMed ID: 27668388
[TBL] [Abstract][Full Text] [Related]
11. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications.
Karanam NK; Story MD
Int J Radiat Biol; 2021; 97(8):1044-1054. PubMed ID: 33086019
[TBL] [Abstract][Full Text] [Related]
12. Rationale and Background on Tumor-Treating Fields for Glioblastoma.
Schwartz MA; Onuselogu L
Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S20-4. PubMed ID: 27668387
[TBL] [Abstract][Full Text] [Related]
13. T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields.
Diamant G; Simchony Goldman H; Gasri Plotnitsky L; Roitman M; Shiloach T; Globerson-Levin A; Eshhar Z; Haim O; Pencovich N; Grossman R; Ram Z; Volovitz I
J Immunol; 2021 Jul; 207(2):709-719. PubMed ID: 34215656
[TBL] [Abstract][Full Text] [Related]
14. Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic.
Gatson NTN; Barnholtz-Sloan J; Drappatz J; Henriksson R; Hottinger AF; Hinoul P; Kruchko C; Puduvalli VK; Tran DD; Wong ET; Glas M
Front Oncol; 2021; 11():679702. PubMed ID: 34026655
[TBL] [Abstract][Full Text] [Related]
15. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
[TBL] [Abstract][Full Text] [Related]
16. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
[TBL] [Abstract][Full Text] [Related]
17. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
[TBL] [Abstract][Full Text] [Related]
18. The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts.
Oberheim-Bush NA; Shi W; McDermott MW; Grote A; Stindl J; Lustgarten L
J Neurooncol; 2022 Jul; 158(3):453-461. PubMed ID: 35639236
[TBL] [Abstract][Full Text] [Related]
19. Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy.
Lee WS; Seo SJ; Chung HK; Park JW; Kim JK; Kim EH
Am J Cancer Res; 2021; 11(9):4582-4594. PubMed ID: 34659907
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma.
Riley MM; San P; Lok E; Swanson KD; Wong ET
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
